Zenas BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zenas BioPharma (ZBIO).

Price Target Range — 7 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$41Upside to Avg. PT+51.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$41→$48
Sep 30, 2026	Wedbush	Martin Fan	Maintained	Outperform	$45
Sep 30, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$44
Aug 14, 2026	Morgan Stanley	Judah Frommer	PT Raise	Equal-Weight	$22→$32
Aug 14, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$55
Aug 14, 2026	Wedbush	Martin Fan	Maintained	Outperform	$45
May 15, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$44
May 14, 2026	Morgan Stanley	Judah Frommer	PT Raise	Equal-Weight	$21→$22
Mar 17, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$43→$41
Mar 17, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$45→$55
Mar 17, 2026	Morgan Stanley	Judah Frommer	PT Raise	Equal-Weight	$19→$21
Mar 17, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$44
Feb 10, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$44
Jan 6, 2026	Morgan Stanley	Judah Frommer	Downgrade	Overweight→Equal-Weight	$37→$19
Dec 22, 2025	Wedbush	Martin Fan	Maintained	Outperform	$45
Nov 26, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$55
Nov 13, 2025	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$34→$37
Oct 28, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$27→$46
Oct 28, 2025	Morgan Stanley	Vikram Purohit	PT Raise	Overweight	$31→$34
Oct 28, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$30→$44

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32

Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.

Benzinga Newsdesk

Zenas BioPharma Inc

Zenas BioPharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

PRO
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32

PRO
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

People Also Watch

People Also Watch

Zenas BioPharma Inc

Zenas BioPharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

PROWedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

PROHC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

PROMorgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32

PROGuggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

PROWedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

PRO
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32

PRO
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

PRO
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target